Benzofuran compounds, compositions, and methods

This invention relates to the fields of pharmaceutical and organic chemistry and provides novel benzofuran compounds which are useful for the treatment of the various medical indications associated with post-menopausal syndrome, and uterine fibroid disease, endometriosis, and aortal smooth muscle ce...

Full description

Saved in:
Bibliographic Details
Main Authors Bryant, Henry U, Cullinan, George J, Dodge, Jeffrey A, Fahey, Kennan J, Jones, Charles D
Format Patent
LanguageEnglish
Published 09.03.2004
Online AccessGet full text

Cover

Loading…
More Information
Summary:This invention relates to the fields of pharmaceutical and organic chemistry and provides novel benzofuran compounds which are useful for the treatment of the various medical indications associated with post-menopausal syndrome, and uterine fibroid disease, endometriosis, and aortal smooth muscle cell proliferation. The present invention further relates to intermediate compounds useful for preparing the pharmaceutically active compounds of the present invention, and pharmaceutical compositions. Furthermore, the present invention relates to a novel process for preparing the pharmaceutically active compounds of the present invention. The present invention provides novel, reduced benzothiophenes of formula I whereinR is -H, -OH, -O(C-Calkyl), -O-CO-(C-Calkyl), -O-CO-Ar in which Ar is optionally substituted phenyl, or -O-SO-(C-Calkyl);Ris -H, -OH, -O(C-Calkyl), -O-CO-(C-Calkyl), -O-CO-Ar in which Ar is optionally substituted phenyl, -O-SO-(C-Calkyl) chloro or bromo;n is 2 or 3; andRand Reach are independently C-Calkyl, or combine to form 1-piperidinyl, 1-pyrrolidino, methyl-1-pyrrolidino, dimethyl-1-pyrrolidino, 4-morpholino or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof. Further provided are methods for alleviating the symptoms of post-menopausal syndrome, and inhibiting endometriosis, uterine fibrosis, and aortal smooth muscle cell proliferation. Also provided are pharmaceutical formulations with formula I compounds, optionally including estrogen or progestin, and intermediate compounds.